WO2009149621A1 - 淫羊藿次苷在制备用于预防或治疗男性或女性性功能障碍的产品中用途 - Google Patents
淫羊藿次苷在制备用于预防或治疗男性或女性性功能障碍的产品中用途 Download PDFInfo
- Publication number
- WO2009149621A1 WO2009149621A1 PCT/CN2009/000650 CN2009000650W WO2009149621A1 WO 2009149621 A1 WO2009149621 A1 WO 2009149621A1 CN 2009000650 W CN2009000650 W CN 2009000650W WO 2009149621 A1 WO2009149621 A1 WO 2009149621A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- icariin
- epimedium
- cells
- activity
- sildenafil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- the present invention relates to the use of icariin II or an extract containing icariin II for the preparation of a product for preventing or treating male or female sexual dysfunction, in particular for improving the pathology or function of an erectile function patient
- Icariin II is a known compound whose structure is as follows:
- icariin has a skin whitening effect (WO2008/035918).
- Male sexual function is mainly caused by a variety of sexual stimuli, a series of hemodynamic changes in the corpus cavernosum caused by the nervous system to cause penile erection.
- the brain and spinal cord erectile modulating central regulation the efferent nerves emitted by the pelvic ganglion cells regulate the function of the corpus cavernosum, and the parasympathetic nerve endings in the efferent nerve release acetylcholine, which activates vascular endothelial cells.
- Endothelial nitric oxide synthase promotes nitric oxide (NO) production, and non-adrenergic non-cholinergic nerve endings activate penile cavernosal smooth muscle neuronal nitric oxide synthase (nNOS), promoting NO production, NO Activation of soluble guanylate cyclization in smooth muscle cells
- the enzyme sGC promotes the increase of cGMP synthesis.
- cGMP-activated proteinase G PKG
- the intracellular calcium ion can be read to induce dilatation of the corpus cavernosum and sinus expansion of the corpus cavernosum.
- the blood perfusion of the penis is rapidly increased, the penis
- the cavernous body expands and the volume increases to oppress the subdural vein and block the venous outflow to increase the pressure in the penis sponge to induce a hard erection of the penis.
- the cGMP in the corpus cavernosum is inactivated by phosphodiesterase type V (PDE5), and the sympathetic nerve excitability increases during ejaculation, which causes the smooth muscle to contract and turn into a weak state.
- sildenafil and other phosphodiesterase (PDE5) inhibitor drugs are inhibited by PDE5, and sexual life can be used to enhance erectile function at one time, nearly 20% of severe organic erectile dysfunction has no effect, and It has no therapeutic effect on the pathophysiological changes of erectile dysfunction, and has various side effects such as flushing, headache, visual disturbance, hypotension, low back pain, etc., especially for patients with cardiovascular disease, and Nitrous acid drugs are strictly contraindicated.
- vascular drugs with smooth muscle relaxation such as paparvar in, Phentolamine, prostaglandin El (pros ta landin El), etc.
- local injection of these drugs directly into the corpus cavernosum can induce the function of penis.
- this therapy has no effect on nearly 20% of severe organic erectile dysfunction, and has no therapeutic effect on the pathophysiological changes of erectile dysfunction, and can reduce the side effects such as headache and dizziness caused by blood pressure, causing local pain, Sustained penile erection, penile fibrosis and other serious side effects are often restricted in clinical use.
- Raw medicine Epimedium is often used as a component in the prescriptions used to nourish strong agents in the traditional medicine industry, but its mechanism of action has not yet been clarified.
- Recent studies on the active ingredients of Epimedium have proven that Epimedium contains many ingredients, such as icariin, icariin I, icariin II, volatile oil, wax alcohol, stearyl alcohol, phytosterols, Tannin, linoleic acid, etc. More recently isolated a trace of magnof lor in, epimedos ide A, epimedin A, B, C 3 ⁇ 4 querecet in, anhydroicar i in-3-0-rhamnos ide and the like.
- Epimedium 3 ⁇ 4 Glycoside is currently only used as a standard reagent for the analysis of Epimedium.
- Previous studies have found that Epimedium II has a selective PDE5 inhibitory effect, but its in vivo strength is found to be significantly lower than that of sildenafil and other chemically synthesized PDE5 inhibitors, preliminary clinical observation of volunteers under informed consent.
- the invention thus relates to the use of icariin I I or an extract containing Icariin I I for the preparation of a product for the prevention or treatment of male or female sexual dysfunction.
- the present invention further relates to a product for preventing or treating a male or female sexual dysfunction comprising icariin I I or an extract containing Epimedium I I and a carrier or an excipient.
- the present invention also relates to a method for preventing or treating male or female sexual dysfunction comprising administering a prophylactically or therapeutically effective amount of icariin II or an extract containing icariin II to a male to be prevented or treated or Female sexual dysfunction patients.
- the present invention relates to the use of epimedium quinone glucoside or an extract containing the same for the preparation of a product for improving pathological/organic tissue in a patient with erectile dysfunction.
- the term "product” means a product usable for a person such as, but not limited to, a health food or a medicine.
- icianin II refers to an extract or mixture of icariin II or icariin II, wherein the extract or mixture is icariin
- the II content is not less than 50% by weight.
- the term "carrier or excipient” means an edible or pharmaceutically acceptable excipient or carrier.
- the invention relates to the prevention and treatment of extracts of icariin and icariin II The use of erectile dysfunction.
- pathological/organic erectile dysfunction accounting for 50% of patients with erectile dysfunction, is caused by damaging changes in the corpus cavernosum, smooth muscle and vascular endothelial cells, and its pathophysiological mechanism and nitric oxide synthase (N0S) Activity and gene protein expression levels are significantly reduced. Therefore, drugs that have a repairing effect on neurological function and smooth muscle function and endothelial cell dysfunction to regulate and repair N0S function and gene protein expression can prevent and treat erectile dysfunction.
- N0S nitric oxide synthase
- the extracts of icariin II and icariin II promote the regeneration of nerve cells, improve the NOS activity of corpus cavernosum smooth muscle and vascular endothelial cells, and the expression of NOS enzyme protein. Moreover, these effects are related to the activating growth factor (EGFR) signaling pathway and thus have an improved, prophylactic or therapeutic effect on the pathological/organic tissue of patients with erectile dysfunction.
- the extract of icariin saponin and icariin 11 used in the present invention may be used singly or in the form of a pharmaceutical composition.
- the pharmaceutical composition comprises as an active ingredient an extract of icariin II and icariin II and a medicinal carrier.
- the extract of icariin saponin and icariin II in the present invention can be used alone or in the form of a pharmaceutical composition for preventing and treating erectile dysfunction, nerve damage disease, endothelial cell function. Prevention and treatment of obstacles.
- the extract of icariin saponin and icariin 11 used in the present invention may be used singly or in the form of a pharmaceutical composition.
- the pharmaceutical composition comprises as an active ingredient an extract of icariin II and icariin II, and the extract of icariin II and icariin II in various dosage forms ranges from 5 mg to 500mg.
- the pharmaceutical composition of the present invention can be prepared by a known method in the art and can be administered orally or parenterally or locally.
- Oral preparations include, for example, tablets, chewables, capsules, suspensions, solutions and the like, and parenteral preparations include, for example, injection solutions.
- Formulations for topical administration include, for example, creams, chondric preparations, patches, sprays and the like.
- the extracts of icariin and icariin II are extracted from a mixture of epimedium and a mixture of an organic solvent or an organic solvent and water, or may be obtained by enzymatic digestion biosynthesis. Extracted from icariin.
- Organic solvents which may be used include alcohols such as methanol, ethanol, etc., 3 ⁇ 4 generation alkanes such as dichloromethane, chloroform, ethers such as diethyl ether, ketones such as acetone, lipids such as decyl acetate, ethyl acetate, hydrocarbons such as Alkane or the like, digestive enzymes include various glucohydrolases or cellulolytic enzymes such as ⁇ -glucose and P-glucose.
- Fig. 3 Effect of icariin I I and sildenafil on NOS activity of vascular endothelial cells (PAE)
- Fig. 4 Effect of nitric oxide synthase inhibitor (LNM) treatment on the activity of ectopic saponins I I on vascular endothelial cells (PAE) N0S
- Fig. 5 Effect of icariin I I and sildenafil on N0S activity of corpus cavernosum smooth muscle cells
- Figure 6 Effect of nitric oxide synthase inhibitor (LNM) on the activity of icariin II in the corpus cavernosum smooth muscle cells
- Fig.7 Effect of epimedium saponins II and sildenafil on cGMP biosynthesis in corpus cavernosum smooth muscle cells
- mice 24 male SD rats aged 24 months old; all animals were smashed Cheng Jun was formally approved by the Animal Protection and Use Committee. Rats were euthanized by intraperitoneal injection of sodium pentobarbital (200 mg/kg) followed by a lower abdominal incision to expose the pelvic ganglion nerve node (MPG) around the prostate. MPG culture and treatment: The MPG of both sides of each rat was obtained by anatomical and complete isolation. After rinsing with phosphate buffered saline (PBS), the MPG was further peeled off to obtain a DCR, which was cut into three pieces of approximately the same size.
- PBS phosphate buffered saline
- RGFM was diluted 3 times in serum-free RPMI-1640 medium in 35 mm culture on ice. The diluted RGFM is tiled onto a cold sterilized glass lid. It was then incubated in a 35 mm Petri dish at 37 for 1 hour to reinforce the RGFM. Subsequently, 40 microdrops of pre-chilled RGFM were added to each MPG block. Incubate for 5 minutes to polymerize the basement membrane, and then add 3 ml of RPMI1640 medium containing no serum containing lx/cyanin, and incubate in a saturated humidity, 5% CO 2 , environment.
- the cultured MPG tissue blocks were randomly divided into 3 groups: blank control group, icariin II and sildenafil group.
- the drug was added to the medium at a concentration gradient of 0, 10, 100 and ⁇ .
- MPGs from 3 younger groups of MGP and 3 older groups were cultured at the indicated doses for 48-72 hours.
- axon growth At 48 and 72 hours, a Nikon DXM1200 digital camera was attached to the Zeiss Axiovert microscope and ACT-1 software to amplify the growth of axons on the MPG 20 times. The digitized image was analyzed using the Chemi Imager 4000 and the longest axon length was calculated. Result
- Porcine vascular endothelial cells were provided by the Institute of Urology, Peking University, and the activity of icariin II on endothelial cells was determined.
- NOS activity was analyzed by NOS reagent: ⁇ (Cayman Chemical company, Ann Arbor, MI, USA) NOS activity (units/mg) - [(val U6-value NO s ) ⁇ (38.3 106)] ⁇ [( 2.15 + The amount of the supernatant) ⁇ (15 ⁇ supernatant volume)] ⁇ [Each cultured egg White concentration].
- PAE 3 ⁇ 4 6.
- 03 ⁇ 0. 61 8.
- 65 ⁇ 0. 87 10.
- 71 ⁇ 0. 98 16.
- 63 19. 1 ⁇ 1.
- 9 18.
- 66 ⁇ 1. 79 Glycoside ⁇
- PAE 03 ⁇ 0. 60 5. 76 ⁇ 0. 56 5. 85 ⁇ 0. 579 6. 32 ⁇ 0. 63 5. 99 ⁇ 0. 58 6. 66 ⁇ 0. 65
- Epimedium saponins II can significantly increase the NOS activity of endothelial cells, and the effect of icariin II on the increase of intracellular NOS activity in EGFR expression, and the effect of icariin II on NOS activity Inhibited by NOS specific inhibitors. This result suggests that icariin I I has a preventive and therapeutic effect on endothelial dysfunction, while sildenafil does not regulate NOS activity.
- Example 4 Mechanism of regulation of eNOS expression in vascular endothelial cells (PAE) by Icariin I I
- pGFP-EGFR was transfected into PAE cells using Qigen's lipofection reagent Ef f ectene. The transfected cells were screened at 800 ug/mL of G418, and single cell clones were obtained and expanded. The expression of EGFR was positive by wes tern blot, and the stable expression of PAE-EGFR was obtained.
- PAE cells and PAE-EGFR cells were plated to 35 mm culture - ⁇ -, 4 disks each. After 12 hours, the final concentration of 12. 5 ⁇ ⁇ icariin I I and sildenafil were treated with PAE-EGFR cells for 24 hr. Subsequently, the drug-treated PAE and PAE-EGFR cells were lysed with RIPA buffer, and the expression of eNOS protein was detected by 8% SDS-PAGE electrophoresis and Wes tern blot. After exposure to the super ECL luminescent substrate, the strip on the X-ray film is scanned by optical density and calibrated with P-act in to form a bar graph.
- PAE cells and PAE-EGFR cells were plated to 35 mm culture medium, 4 plates each. After 12 hours, PAE and PAE-EGFR cells were treated with a final concentration of 12. 5 ⁇ ⁇ icariin I I and sildenafil alone or with 100 ⁇ g/ ⁇ L EGF for 24 hr. Subsequently, the drug-treated PAE and PAE-EGFR cells were lysed with RIPA buffer, and the expression of eNOS protein was detected by 8% SDS-PAGE electrophoresis and Wes tern blot. After exposure to the super ECL luminescent substrate, the bands on the X-ray film were scanned by optical density and calibrated with ⁇ -actin to form a bar graph.
- Icariin I I may activate EGFR to regulate the expression of eNOS enzyme protein in endothelial cells, while sildenafil has no significant effect on eNOS protein expression.
- etoposide I I regulates eNOS expression in endothelial cells and may be related to the activity of growth factor (EGFR) signaling pathway, which needs further study.
- EGFR growth factor
- CCSMCs Primary cultured human corpus cavernosum smooth muscle
- N0S activity [( va lue N0S - measure_ va lue NOS-blank) ⁇ (38. 3 ⁇ 106) ] ⁇ [ (2. 15+ supernatant volume) ⁇ (15 S supernatant) Liquid volume)] ⁇ [protein concentration in each well].
- the NOS activity in CCSMCs was 0.46 units/mg without drug treatment.
- concentration reached 10-8 M
- the icariin produced a significant effect (P ⁇ 0.05), and the N0S activity was 1. 59 units / mg protein, respectively.
- concentration reached 10-6 M
- the effect of Icariin I I peaked, and the N0S activity at this time was 4.19 units/mg protein, respectively.
- the statistical difference was more significant at concentrations of 10-7, 10-6 and 10- 5 M (P ⁇ 0.01). Prior to reaching 10-6 M, the effect of Icariin I I on N0S activity was dose-dependent. However, there is no statistical difference in the sildenafil group.
- the N0S activity in CCSMCs decreased to an average of 0.3 units/mg protein.
- icariin I I was able to increase N0S activity in a dose-dependent manner until the concentration reached 10-6 M.
- the increase of N0S activity in the LMA group was not significant (P ⁇ 0.05); the peak of N0S activity decreased to 2.67 units/mg. There were statistical differences in concentrations between 10-7, 10-6 and 10-5 M.
- CCSMCs Primary cultured human corpus cavernosum smooth muscle
- cGMP concentration [pmol/(mg prot - min)] [cGMP or cAMP concentration x supernatant volume] ⁇ reaction time X protein concentration per well X supernatant volume].
- the concentrations of cGMP and cAMP in CCSMCs were 0. 42 and 5. 16 pmol/(mg prot ⁇ min), respectively, without drug treatment. Icariin I I and sildenafil had no significant effect on the concentration of cAMP (P>0.05).
- Icariin II and sildenafil have a significant effect on cGMP biosynthesis in corpus cavernosum smooth muscle cells, and icariin II is significantly less effective against cGMP than sildenafil. Icariin II and sildenafil did not significantly affect cAMP biosynthesis in corpus cavernosum smooth muscle cells. This result suggests that Epimedium II has a certain inhibitory effect on PDE5.
- Example 6 Effect of Epimedium Glucoside on Regulation of N0S Subtype Gene and Protein Expression in Corpus Cavernous Smooth Muscle Cells
- RESULTS The results of RT-PCR showed that icariin saponins treated corpus cavernosum smooth muscle cells significantly increased nNOS ' mRNA levels after 1 day and 2 days (P ⁇ 0.05, P ⁇ 0.01), and iNOS also increased slightly. ( ⁇ 0.05), while eNOS mRNA did not change. The PDE5a mRNA level was significantly decreased ( ⁇ 0.05). Sildenafil treatment significantly reduced PDE5a mRNA levels at 1 and 2 days (P ⁇ 0, 05, P ⁇ 0.01), and iNOS also after 2 days. There was a slight increase, but no significant changes in eNOS and nNOS mRNA were observed at 1 and 2 days.
- I IEF International Functional Assessment Form
- the experimental drug Icariin I I extract (containing Icariin I I 51%) was made into a capsule (containing 200% of Icariin I per gum), similar to the packaging of the placebo group. Both the illuminant and the medicinal agent did not know the conditions of the drug information.
- the selected volunteers were not randomly divided into two groups, the icariin I I challenge group and the placebo group.
- the patients took placebo or experimental drugs (1 capsule/time) before going to sleep for 4 weeks.
- the patients were given a sexual function evaluation questionnaire (5 in total, 5 degrees each) before and after taking the drug. The sexual function changes before and after the drug were compared by the Student t test.
- the results of the study were evaluated before the treatment of the patient's sexual function score (I IEF5) in the treatment group and the placebo group, 12, 6 and 13. 2, after treatment, the treatment group and the placebo group I IEF5
- the scores were 19.54 ⁇ 3. 67 and 14.23 ⁇ 2. 97, and the placebo was significantly improved by taking the icariin II capsule group (p ⁇ 0.05).
- the overall clinical effect of the icariin II capsule group and the placebo group were 71.41% and 41.48%, respectively. No significant side effects were found except for 3 patients with mild gastrointestinal reactions. There were no significant differences in clinical outcomes and side effects between patients with diabetes, hypertension, and heart disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09761246.9A EP2305273B1 (en) | 2008-06-13 | 2009-06-12 | Use of icariside II for the prevention or treatment of erectile dysfunction |
KR1020117000360A KR101456953B1 (ko) | 2008-06-13 | 2009-06-12 | 이카리시드 ii의 남성 또는 여성 성기능장애의 예방 또는 치료제 제조에서의 용도 |
US12/997,423 US8530433B2 (en) | 2008-06-13 | 2009-06-12 | Use of icariside II in manufacture of products for preventing or treating male or female sexual dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810110687.9 | 2008-06-13 | ||
CN200810110687 | 2008-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009149621A1 true WO2009149621A1 (zh) | 2009-12-17 |
Family
ID=41416355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000650 WO2009149621A1 (zh) | 2008-06-13 | 2009-06-12 | 淫羊藿次苷在制备用于预防或治疗男性或女性性功能障碍的产品中用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8530433B2 (zh) |
EP (1) | EP2305273B1 (zh) |
KR (1) | KR101456953B1 (zh) |
WO (1) | WO2009149621A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108392487A (zh) * | 2018-02-24 | 2018-08-14 | 苏州广奥医药开发有限公司 | 一种淫羊藿次苷ⅱ或其可药用载体在勃起功能障碍中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1199647C (zh) * | 1999-06-17 | 2005-05-04 | 北京东方百奥医药开发有限公司 | 淫羊藿甙在制备用于预防或治疗勃起功能障碍的药物中用途 |
WO2007064085A1 (en) * | 2005-11-30 | 2007-06-07 | Amorepacific Corporation | Cosmetic composition containing hydrolysates of icariin |
WO2008035918A1 (en) | 2006-09-19 | 2008-03-27 | Amorepacific Corporation | Method for preparing icariside ii, cosmetic composition containing the same and the use thereof for skin whitening |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6916845B2 (en) * | 1999-06-17 | 2005-07-12 | Zhongcheng Xin | Method for prevention and treatment of male and female sexual dysfunction |
US6399579B1 (en) * | 2000-08-15 | 2002-06-04 | Hauser, Inc. | Compositions comprising icariside I and anhydroicaritin and methods for making the same |
US7658956B2 (en) * | 2006-07-28 | 2010-02-09 | Jose Angel Olalde Rangel | Erectile dysfunction phyto-nutraceutical synergistic composition |
KR100821683B1 (ko) * | 2006-11-01 | 2008-04-15 | 우석대학교 산학협력단 | 이카리사이드 Ⅱ (icariside Ⅱ)를 유효성분으로 하는 혈관 형성 장애 관련 질환의 예방 및 치료용 조성물 |
-
2009
- 2009-06-12 WO PCT/CN2009/000650 patent/WO2009149621A1/zh active Application Filing
- 2009-06-12 KR KR1020117000360A patent/KR101456953B1/ko active IP Right Grant
- 2009-06-12 US US12/997,423 patent/US8530433B2/en active Active
- 2009-06-12 EP EP09761246.9A patent/EP2305273B1/en not_active Not-in-force
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1199647C (zh) * | 1999-06-17 | 2005-05-04 | 北京东方百奥医药开发有限公司 | 淫羊藿甙在制备用于预防或治疗勃起功能障碍的药物中用途 |
WO2007064085A1 (en) * | 2005-11-30 | 2007-06-07 | Amorepacific Corporation | Cosmetic composition containing hydrolysates of icariin |
WO2008035918A1 (en) | 2006-09-19 | 2008-03-27 | Amorepacific Corporation | Method for preparing icariside ii, cosmetic composition containing the same and the use thereof for skin whitening |
Non-Patent Citations (1)
Title |
---|
ZHAO YANHONG ET AL.: "Studies on rat intestinal absorption of the total flavones of epimedium in situ.", CHIN PHARM J(CHINESE)., vol. 43, no. 3, February 2008 (2008-02-01), pages 191, XP008140303 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108392487A (zh) * | 2018-02-24 | 2018-08-14 | 苏州广奥医药开发有限公司 | 一种淫羊藿次苷ⅱ或其可药用载体在勃起功能障碍中的应用 |
WO2019161719A1 (zh) * | 2018-02-24 | 2019-08-29 | 苏州广奥医药开发有限公司 | 一种淫羊藿次苷ⅱ或其可药用载体在勃起功能障碍中的应用 |
CN108392487B (zh) * | 2018-02-24 | 2023-09-01 | 北京东方百奥医药开发有限公司 | 一种淫羊藿次苷ⅱ或其可药用载体在勃起功能障碍中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2305273B1 (en) | 2018-08-15 |
US8530433B2 (en) | 2013-09-10 |
KR101456953B1 (ko) | 2014-10-31 |
EP2305273A1 (en) | 2011-04-06 |
KR20110025961A (ko) | 2011-03-14 |
US20110301106A1 (en) | 2011-12-08 |
EP2305273A4 (en) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102526165B (zh) | 一种红景天有效部位、其制备方法、其药物组合物及用途 | |
WO2008031322A1 (fr) | Application d'un médicament inhibiteur d'acétylcholine estérase à base d'un extrait de leonurus utilisé en tant que cholinomimétique | |
JP2012140437A (ja) | 肥満、肥満に関連する障害、および他の障害の治療/管理におけるプレグナン配糖体の使用 | |
CN110996987A (zh) | 用于调控应激障碍中激素级联的组合物和方法 | |
WO2005003145A1 (en) | Shanzhuyu extract and uses thereof | |
JP2008521839A (ja) | 大葉(叶)蒟抽出物の調製方法、抽出物及びその応用 | |
JPS5835117A (ja) | 新規生理活性物質nsh | |
CN103181941A (zh) | 淫羊藿苷或淫羊藿次苷ⅱ在制备防治糖尿病视网膜病变的药物中的用途 | |
CN107106624A (zh) | 预防、改善或治疗退行性神经系统疾病的含桑葚和茯苓皮的混合提取物的组合物 | |
JP5435951B2 (ja) | コリナンテ種の樹皮からの抽出物、その使用、およびそれを含有する薬剤、ダイエット食品および医薬品 | |
CN102512431B (zh) | 积雪草三萜类成分在用于制备抗颅脑损伤产品中的应用 | |
CN101129394B (zh) | 秦皮甲素预防和/或治疗心脑血管疾病的新用途 | |
JP2001278796A (ja) | 抗痒み・抗アレルギー組成物 | |
JP4864259B2 (ja) | 性機能障害および血管収縮に関する疾患の予防および治療におけるイカリンの使用 | |
WO2009149621A1 (zh) | 淫羊藿次苷在制备用于预防或治疗男性或女性性功能障碍的产品中用途 | |
RU2548794C2 (ru) | Ингибитор эластазы | |
CN101152223B (zh) | 杨树叶酚类提取物在制备治疗心律失常的药物中的应用 | |
WO2009062374A1 (fr) | Utilisation pharmaceutique de liquiritigénine pour préparer un médicament destiné au traitement de maladies neurodégénératives | |
KR102157247B1 (ko) | 김 추출물을 함유하는 가려움증의 개선, 예방 또는 치료용 조성물 | |
US6916845B2 (en) | Method for prevention and treatment of male and female sexual dysfunction | |
WO2019114676A1 (zh) | 一种柿叶提取物及其制剂的新医药用途 | |
KR20140127874A (ko) | 요실금 및 야뇨증을 치료하기 위한 약학적 조성물 | |
JPH05503089A (ja) | 薬理学的活性物質bpc、その製造方法及びこれを治療に使用する方法 | |
EP2830641B1 (en) | New valerian extracts and uses thereof | |
CN102552481A (zh) | 一种通络降压中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09761246 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117000360 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009761246 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12997423 Country of ref document: US |